ATE168415T1 - Wasserlösliche peptidanaloguen mit bindungstellen - Google Patents
Wasserlösliche peptidanaloguen mit bindungstellenInfo
- Publication number
- ATE168415T1 ATE168415T1 AT91909574T AT91909574T ATE168415T1 AT E168415 T1 ATE168415 T1 AT E168415T1 AT 91909574 T AT91909574 T AT 91909574T AT 91909574 T AT91909574 T AT 91909574T AT E168415 T1 ATE168415 T1 AT E168415T1
- Authority
- AT
- Austria
- Prior art keywords
- complement
- water soluble
- binding sites
- peptide analogues
- directed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Led Devices (AREA)
- Led Device Packages (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51329990A | 1990-04-25 | 1990-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE168415T1 true ATE168415T1 (de) | 1998-08-15 |
Family
ID=24042678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91909574T ATE168415T1 (de) | 1990-04-25 | 1991-04-25 | Wasserlösliche peptidanaloguen mit bindungstellen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6458360B1 (de) |
EP (1) | EP0528926B1 (de) |
JP (1) | JPH05507197A (de) |
AT (1) | ATE168415T1 (de) |
AU (1) | AU7876691A (de) |
CA (1) | CA2081207A1 (de) |
DE (1) | DE69129803D1 (de) |
WO (1) | WO1991016437A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5709859A (en) * | 1991-01-24 | 1998-01-20 | Bristol-Myers Squibb Company | Mixed specificity fusion proteins |
GB9424631D0 (en) * | 1994-12-06 | 1995-01-25 | Lynxvale Ltd | Modulating the immune response |
BR9707325A (pt) | 1996-02-09 | 1999-04-13 | Amgen Inc | Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
GB9614871D0 (en) | 1996-07-15 | 1996-09-04 | Smithkline Beecham Plc | Compounds |
CA2273852C (en) | 1996-12-06 | 2009-09-29 | Amgen Inc. | Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases |
AU3066699A (en) | 1998-03-03 | 1999-09-20 | Johns Hopkins University, The | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
US6820011B2 (en) | 2001-04-11 | 2004-11-16 | The Regents Of The University Of Colorado | Three-dimensional structure of complement receptor type 2 and uses thereof |
EP1387697A4 (de) * | 2001-05-17 | 2005-04-20 | Jolla Pharma | Verfahren zur behandlung von antikörper-vermittelten erkrankungen unter verwendung von mitteln zur hemmung von cd21 |
ES2392511T3 (es) * | 2002-11-15 | 2012-12-11 | Musc Foundation For Research Development | Moduladores de complemento dianas sobre el receptor 2 de complemento |
US20060140939A1 (en) * | 2003-02-21 | 2006-06-29 | Fung Sek C M | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
US8454963B2 (en) * | 2003-11-13 | 2013-06-04 | Musc Foundation For Research Development | Tissue targeted complement modulators |
US8124097B2 (en) * | 2004-01-21 | 2012-02-28 | Case Western Reserve University | Hybrid and chimeric polypeptides that regulate activation of complement |
PT1713503E (pt) * | 2004-02-10 | 2013-11-14 | Nat Jewish Health | Inibição do factor b, a via alternativa do complemento e métodos relacionados |
WO2005116071A2 (en) * | 2004-05-28 | 2005-12-08 | University Of Massachusetts | Snares for pathogenic or infectious agents and uses related thereto |
ES2548700T3 (es) * | 2005-05-26 | 2015-10-20 | The Regents Of The University Of Colorado, A Body Corporate | Inhibición de la vía alternativa del complemento para el tratamiento de lesión cerebral traumática, lesión de médula espinal y afecciones relacionadas |
WO2007045465A1 (en) | 2005-10-21 | 2007-04-26 | F. Hoffmann-La Roche Ag | Method for the recombinant expression of a polypeptide |
CN101563363B (zh) | 2006-06-21 | 2013-01-02 | 南卡罗来纳医疗大学研究发展基金会 | 用于治疗疾病的靶向补体因子h |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
CA2666843C (en) * | 2006-10-20 | 2015-06-16 | Celldex Therapeutics, Inc. | Treatment of age-related macular degeneration and other diseases of the eye |
EP2236518B1 (de) | 2007-03-14 | 2014-08-06 | Alexion Cambridge Corporation | Humanisierter Antikörper gegen Faktor B |
US8937046B2 (en) | 2008-09-22 | 2015-01-20 | The Regents Of The University Of Colorado, A Body Corporate | Modulating the alternative complement pathway |
RS20120461A1 (en) | 2009-07-02 | 2013-06-28 | Musc Foundation For Research Development | METHODS FOR STIMULATION OF LIVER REGENERATION |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
AU2010314931A1 (en) | 2009-11-05 | 2012-06-21 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
HUE046670T2 (hu) | 2010-01-15 | 2020-03-30 | Kirin Amgen Inc | Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére |
JP5986990B2 (ja) | 2010-05-14 | 2016-09-06 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド,ア ボディ コーポレート | 改善された補体レセプター2(cr2)ターゲティング基 |
WO2011163412A1 (en) | 2010-06-22 | 2011-12-29 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the c3d fragment of complement component 3 |
CN103237557A (zh) | 2010-09-15 | 2013-08-07 | 赛尔戴克斯治疗公司 | 用可溶性I型补体受体(sCR1)治疗慢性肾病 |
CA2815237C (en) | 2010-10-27 | 2018-10-09 | Celldex Therapeutics, Inc. | Method of improving transplant function using soluble complement receptor type i (scr1) |
US20120148542A1 (en) | 2010-12-10 | 2012-06-14 | Lifeline Scientific, Inc. | Machine perfusion with complement inhibitors |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
EP2855529A4 (de) | 2012-05-24 | 2015-12-09 | Alexion Pharma Inc | Humanisierte anti-faktor-b-antikörper |
AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
WO2014113510A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
AU2015241373B2 (en) | 2014-03-31 | 2020-11-05 | Amgen K-A, Inc. | Methods of treating nail and scalp psoriasis |
US20160060360A1 (en) | 2014-07-24 | 2016-03-03 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5212071A (en) | 1988-04-01 | 1993-05-18 | The Johns Hopkins University | Nucleic acids encoding a human C3b/C4b receptor (CR1) |
NZ191320A (en) | 1978-09-07 | 1982-09-14 | Beecham Group Ltd | In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions |
EP0028489B1 (de) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzym-Derivate und ihre Herstellung |
US4642284A (en) | 1983-06-13 | 1987-02-10 | Scripps Clinic And Research Foundation | Method and system for detection of complement pathway activation |
US4672044A (en) | 1984-08-24 | 1987-06-09 | Scripps Clinic & Research Foundation | Murine monoclonal antibody combining site to human C3b receptor (CR1) |
US4761371A (en) | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
JPH0742235B2 (ja) | 1985-11-08 | 1995-05-10 | 三共株式会社 | 自己免疫性疾病の予防・治療剤 |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4894226A (en) | 1986-11-14 | 1990-01-16 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polyproline conjugation |
ATE114723T1 (de) | 1987-03-02 | 1994-12-15 | Enzon Lab Inc | Organismus als träger für ''single chain antibody domain (scad)''. |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
ZA89430B (en) | 1988-01-22 | 1989-10-25 | Gen Hospital Corp | Cloned genes encoding ig-cd4 fusion proteins and the use thereof |
EP0325224B1 (de) * | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
US4937183A (en) | 1988-02-03 | 1990-06-26 | Cytogen Corporation | Method for the preparation of antibody-fragment conjugates |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
IL89790A (en) * | 1988-04-01 | 2002-05-23 | Johns Hopking University | Sequences of nucleic acids encoding and cells producing CR1 protein and methods for its production and purification |
AU4341189A (en) | 1988-10-03 | 1990-05-01 | Scripps Clinic And Research Foundation | The receptor binding region of ebvgp350 |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
AT402153B (de) | 1989-06-26 | 1997-02-25 | Immuno Ag | Protein-s-hältige pharmazeutische präparation |
US5314995A (en) * | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
-
1991
- 1991-04-04 US US07/949,472 patent/US6458360B1/en not_active Expired - Fee Related
- 1991-04-25 CA CA002081207A patent/CA2081207A1/en not_active Abandoned
- 1991-04-25 DE DE69129803T patent/DE69129803D1/de not_active Expired - Lifetime
- 1991-04-25 WO PCT/US1991/002852 patent/WO1991016437A1/en active IP Right Grant
- 1991-04-25 AU AU78766/91A patent/AU7876691A/en not_active Abandoned
- 1991-04-25 EP EP91909574A patent/EP0528926B1/de not_active Expired - Lifetime
- 1991-04-25 AT AT91909574T patent/ATE168415T1/de not_active IP Right Cessation
- 1991-04-25 JP JP91509369A patent/JPH05507197A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69129803D1 (de) | 1998-08-20 |
EP0528926A1 (de) | 1993-03-03 |
AU7876691A (en) | 1991-11-11 |
US6458360B1 (en) | 2002-10-01 |
CA2081207A1 (en) | 1991-10-26 |
JPH05507197A (ja) | 1993-10-21 |
WO1991016437A1 (en) | 1991-10-31 |
EP0528926B1 (de) | 1998-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE168415T1 (de) | Wasserlösliche peptidanaloguen mit bindungstellen | |
ATE194382T1 (de) | Neuartige polypeptide zur unterstützung der zellfixierung | |
DK1642973T3 (da) | Terapeutisk anvendelser af BR43X2-oplöselige receptorer | |
ATE136908T1 (de) | Peptide und antikörper, die die integrin- ligandbindung inhibieren | |
Bailey et al. | Partial characterization of a second basement membrane collagen in human placenta: evidence for the existence of two type IV collagen molecules | |
DK161015C (da) | Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop | |
IL96043A0 (en) | Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known | |
NZ512083A (en) | Methods of increasing lean tissue mass using OB protein compositions | |
ATE229342T1 (de) | Verwendung von interleukin-15 | |
DE69132275D1 (de) | Beta-type ähnlicher transformierender wachstumfaktor | |
KR950704489A (ko) | 인터페론 타우 조성물 및 사용방법(interferon tau compositions and methods of use) | |
ES550943A0 (es) | Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana. | |
DE68927379D1 (de) | Plättchen blockierende peptide | |
EA200000685A1 (ru) | Комплекс ifnar2/ifn | |
DK611386A (da) | Recombinant humant fsh, fremgangsmaade til fremstilling deraf og vektorer og celler til anvendelse ved fremgangsmaaden | |
DE69331501D1 (de) | Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin | |
ATE223481T1 (de) | Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator | |
ES2129120T3 (es) | Un receptor de celulas t humanas de la familia de receptores acoplados a la proteina g. | |
DK0404967T3 (da) | Rekombinante C-terminal-alfa-amiderende enzym af human skjoldbruskkirtel-oprindelse | |
Benhamini et al. | Immunochemical studies with synthetic peptides related to collagen | |
DE69032096D1 (de) | Antikörper gegen das carboxy-terminale Peptid des Somatotropin-Bindungsproteins der Ratte | |
JPS6460388A (en) | Gene coding linked material of protein a-like substance fc bond region, recombinant plasmid containing said gene and transformant produced by using said recombinant plasmid | |
KR970061914A (ko) | 생물학적으로 유용한 펩타이드 | |
EA199900432A1 (ru) | Ice-ингибирующие пептиды |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |